Equities Analysts Set Expectations for Repligen Q2 Earnings

Repligen Co. (NASDAQ:RGEN - Free Report) - Analysts at Leerink Partnrs dropped their Q2 2025 earnings per share (EPS) estimates for shares of Repligen in a research note issued to investors on Tuesday, April 29th. Leerink Partnrs analyst P. Souda now expects that the biotechnology company will earn $0.39 per share for the quarter, down from their previous forecast of $0.42. The consensus estimate for Repligen's current full-year earnings is $1.72 per share. Leerink Partnrs also issued estimates for Repligen's Q3 2025 earnings at $0.39 EPS, FY2025 earnings at $1.67 EPS and FY2026 earnings at $2.14 EPS.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share for the quarter, topping analysts' consensus estimates of $0.35 by $0.04. The firm had revenue of $169.17 million during the quarter, compared to analyst estimates of $163.65 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. Repligen's revenue for the quarter was up 10.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.28 earnings per share.

A number of other research firms also recently issued reports on RGEN. JPMorgan Chase & Co. reduced their price objective on Repligen from $200.00 to $190.00 and set an "overweight" rating on the stock in a research note on Tuesday, April 29th. Canaccord Genuity Group cut their target price on shares of Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a report on Wednesday, April 16th. HC Wainwright reaffirmed a "buy" rating and set a $180.00 price target on shares of Repligen in a research note on Monday. TD Cowen started coverage on shares of Repligen in a research note on Monday, February 10th. They issued a "buy" rating and a $200.00 price objective for the company. Finally, Royal Bank of Canada decreased their target price on shares of Repligen from $202.00 to $189.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 30th. Six investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $173.25.

Repligen Price Performance

Shares of RGEN stock traded down $3.07 during trading hours on Friday, hitting $127.34. The stock had a trading volume of 681,683 shares, compared to its average volume of 720,563. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The stock has a market capitalization of $7.15 billion, a price-to-earnings ratio of -249.68, a PEG ratio of 4.54 and a beta of 1.21. Repligen has a one year low of $102.97 and a one year high of $182.52. The stock's 50-day moving average price is $136.86 and its two-hundred day moving average price is $145.74.

Institutional Trading of Repligen

A number of large investors have recently made changes to their positions in the stock. UMB Bank n.a. lifted its holdings in Repligen by 49.1% during the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock valued at $48,000 after buying an additional 110 shares in the last quarter. Oppenheimer & Co. Inc. bought a new position in Repligen in the fourth quarter worth approximately $216,000. Van ECK Associates Corp grew its stake in Repligen by 7.8% in the fourth quarter. Van ECK Associates Corp now owns 42,226 shares of the biotechnology company's stock worth $6,078,000 after purchasing an additional 3,066 shares in the last quarter. Stephens Investment Management Group LLC increased its holdings in Repligen by 7.4% during the 4th quarter. Stephens Investment Management Group LLC now owns 536,801 shares of the biotechnology company's stock worth $77,267,000 after purchasing an additional 37,057 shares during the period. Finally, Artemis Investment Management LLP raised its position in Repligen by 18.4% during the 4th quarter. Artemis Investment Management LLP now owns 153,832 shares of the biotechnology company's stock valued at $22,143,000 after purchasing an additional 23,905 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Repligen news, Director Margaret Pax acquired 250 shares of the company's stock in a transaction that occurred on Monday, March 17th. The stock was bought at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the acquisition, the director now directly owns 1,043 shares in the company, valued at $157,169.67. The trade was a 31.53 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 1.20% of the company's stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.